[Cases of fraud in publications: From Darsee to Poldermans].
Fraud in biomedical literature has been highlighted by recent cases referring to key opinion leaders responsible for "massive" fake due to the number of papers published with made-up data in peer-review journals with high impact factor. Editors have an increasing responsibility in preventing publication of culprit studies, leading to check not only the value and the interpretation of submitted data but the whole process of elaborating protocols and performing studies. Increased transparency in clinical trials performance is critical to prevent biomedical fraud.
Assistance publique-Hôpitaux de Paris, hôpital Tenon, université Pierre-et-Marie-Curie, Paris VI, service d'anesthésie-réanimation, 75020 Paris, France. francis.bonnet@tnn.aphp.fr
Francis
F
Bonnet
Charles Marc
CM
Samama
D001319:Authorship; D035843:Biomedical Research / Q000941:ethics; D002986:Clinical Trials as Topic / Q000941:ethics; D035081:Editorial Policies; D005607:Fraud / Q000517:prevention & control; D006801:Humans; D055811:Journal Impact Factor; D009316:National Institutes of Health (U.S.); D010506:Periodicals as Topic; D011643:Publishing; D012180:Retraction of Publication as Topic; D015871:Scientific Misconduct; D014481:United States